Zealand Pharma — Februar 2024
-
Godmorgen
-
Zealand Pharma får løftet kursmålet gevaldigt hos to amerikanske storbanker https://www.proinvestor.com/investornyt/1124234/zealand-pharma-far-loftet-kursmalet-gevaldigt-hos-to-amerikanske-storbanker
-
Shortpositioner på danske aktier: https://oam.finanstilsynet.dk/#!/stats-and-extracts-short-net-positions
-
Mornings - oven i GS og Jeff´s nye høje kursmål SEB 715(565)
-
-
Jefferies raises target price on Zealand Pharma
to DKK 790 from DKK 485, says it sees the Danish company's liver
drug Survodutide potentially reaching $10 bln in peak sales -
Jefferies says it views co as "a key player in next wave
of obesity therapeutics", given the overlap of liver disease
with obesity, and expects the share value to continue growing -
The broker also has high hopes for the Q2 2024 data on
diabetes drug Amylin, which is also used for obesity, seeing a
50% probability of success -
@ Bullish : Både og....købte 1/3 tilbage og satsede de andre 2/3 på Gubra, da de havde regnskab i dag...håbede på gode nyheder,...hvilket lige pt. var en ok ide, da de er oppe med 15%...Sidder med fingeren på salgsknappen og venter på et dip...Tænker både ZP og Gubra dipper lidt inden for nær fremtid, og så bytter jeg måske om igen...eller sælger det hele og smider det i SMSMED....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind